Abstract
What effect will the war on bioterrorism have on biotechnology patents? This editorial argues that political organisations that view patents as immoral and as a barrier to providing public health in developing countries have capitalised on concerns about the availability of drugs and vaccines to treat bioterrorist threats to undermine patent protection in the US. In fact, patent protection does not prohibit access to medicines or prevent effective response to bioterrorism. On the contrary, patent protection and the creation of markets for new technologies are critical to supporting next generation products that can win the war against future outbreaks.